Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

The role of a new generation Hartman-Shack aberrometer in wavefront-guided IntraLase LASIK for myopia and myopic astigmatism: a retrospective analysis

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Keratorefractive Results II

Venue: Poster Village: Pod 2

First Author: : D.Mathur INDIA

Co Author(s): :    R. Dutta   N. Shroff           

Abstract Details


To evaluate the safety and efficacy of wavefront guided laser in situ keratomileusis of myopia and myopic astigmatism from data generated from a new sensor technology (iDesign Advanced WaveScan Aberrometer).


Cornea & Refractive Service, Shroff Eye Centre, A-9, Kailash Colony, New Delhi - 110048, India.


This retrospective study analyzed a group of eyes treated with wavefront guided LASIK for myopia and myopic astigmatism using the VISX STAR S4IR and the IntraLase iFS 150 with wavefront data derived from the iDesign Hartman-Shack WaveScan Aberrometer. The primary outcome measures recorded were uncorrected distance visual acuity (UDVA), Corrected Distance Visual Acuity (CDVA), predictability & refractive accuracy, amount of higher order aberrations, and overall patient satisfaction at 1 month, 6 months and 12 months.


This study included 302 eyes of 171 patients. The mean decimal UDVA improved from 0.09 ± 0.22 preoperatively, to 1.01 ± 0.26 post-operatively (p<.01). Post-operative manifest spherical equivalent was within ±0.5D in all eyes. UDVA of 20/16 and 20/20 was achieved in 82.2% and 98.6% of all eyes respectively. No eye lost one or more lines of best-corrected visual acuity. 45.6% of all eyes gained 1 or more lines of corrected distance visual acuity.


Using the newer Hartman-Shack Aberrometer (iDesign Advanced WaveScan) for wavefront-guided LASIK in treating myopia and myopic astigmatism was safe, effective, and predictable with an overall reduction of higher order aberrations and high patient satisfaction.

Financial Disclosure:


Back to previous